Andrew Grigg mainly focuses on Internal medicine, Surgery, Leukemia, Immunology and Imatinib. His Internal medicine research incorporates elements of Gastroenterology and Oncology. The various areas that Andrew Grigg examines in his Surgery study include Clinical trial, Incidence and Hazard ratio.
The concepts of his Leukemia study are interwoven with issues in Autoimmune disease, Allogeneic transplantation and Intensive care medicine. His Immunology study integrates concerns from other disciplines, such as Hematopoietic stem cell transplantation, Neutropenia and Fludarabine. His work deals with themes such as Chronic myelogenous leukemia and Tyrosine-kinase inhibitor, which intersect with Imatinib.
His main research concerns Internal medicine, Surgery, Transplantation, Oncology and Immunology. Internal medicine and Gastroenterology are frequently intertwined in his study. His Gastroenterology research is multidisciplinary, relying on both Granulocyte colony-stimulating factor and Fludarabine.
Andrew Grigg combines subjects such as Stem cell and Bone marrow with his study of Transplantation. His Oncology study combines topics from a wide range of disciplines, such as Lymphoma and Rituximab. His Imatinib research incorporates themes from Chronic myelogenous leukemia and Tyrosine-kinase inhibitor.
Andrew Grigg focuses on Internal medicine, Oncology, Transplantation, Chemotherapy and Stem cell. Internal medicine is a component of his Asymptomatic, Hematology, Lymphoma, Retrospective cohort study and Rituximab studies. Andrew Grigg has researched Oncology in several fields, including Follicular lymphoma, Dexamethasone, Cohort and Clinical trial.
His work carried out in the field of Transplantation brings together such families of science as Congenital cytomegalovirus infection, Nivolumab and Leukemia, Immunology. His research in Leukemia intersects with topics in Myeloid and Imatinib. His research investigates the connection between Chemotherapy and topics such as Brentuximab vedotin that intersect with issues in Stage and Doxorubicin.
The scientist’s investigation covers issues in Internal medicine, Oncology, Chemotherapy, Transplantation and Hematology. Rituximab, Diffuse large B-cell lymphoma, Imatinib, Incidence and Adverse effect are the core of his Internal medicine study. His biological study spans a wide range of topics, including Progression-free survival, Phases of clinical research, Chronic myelogenous leukemia, Follicular lymphoma and Nivolumab.
His Transplantation research is multidisciplinary, incorporating elements of Prednisolone, Humoral immunity, Antibody, Immunology and Stem cell. His Hematology research includes elements of Cytarabine and Disease. In his research on the topic of Myeloid leukemia, Imatinib mesylate is strongly related with Leukemia.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
Susan Branford;Zbigniew Rudzki;Sonya Walsh;Ian Parkinson.
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.
Susan Branford;Zbigniew Rudzki;Sonya Walsh;Andrew Grigg.
Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia
Harrison Cn;Campbell Pj;Buck G;Wheatley K.
The New England Journal of Medicine (2005)
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M. Ross;Susan Branford;John F. Seymour;Anthony P. Schwarer.
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Camille Abboud;Ellin Berman;Adam Cohen.
An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study
G. M. Mead;M. R. Sydes;J. Walewski;A. Grigg.
Annals of Oncology (2002)
Optimizing Dose and Scheduling of Filgrastim (Granulocyte Colony- Stimulating Factor) for Mobilization and Collection of Peripheral Blood Progenitor Cells in Normal Volunteers
Andrew P. Grigg;Andrew W. Roberts;Heike Raunow;Sue Houghton.
A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease
Mary E D Flowers;Jane F. Apperley;Koen Van Besien;Ahmet Elmaagacli.
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR
David Ross;Susan Branford;John F Seymour;Anthony Schwarer.
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)
Harry J. Iland;Harry J. Iland;Ken Bradstock;Ken Bradstock;Shane G. Supple;Alberto Catalano.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: